If you’re diagnosed with lazy eye -- otherwise known as amblyopia -- as a child, there are only a few options at your disposal. You can wear an eye patch, you can take eye drops or you can wear ...

Scott Xiao was a freshman student at Harvard when he first learned of amblyopia. Colloquially known as “lazy eye,” the condition affected one of his classmates and Xiao was moved by their treatment ...

Please provide your email address to receive an email when new articles are posted on . Luminopia improved distance control scores after 3 months of treatment. The therapy has the potential to be the ...

Please provide your email address to receive an email when new articles are posted on . Real-world Luminopia data showed clinically meaningful visual acuity gains in severe amblyopia. Other studies ...

Luminopia was honored for its innovative, FDA-cleared treatment for pediatric amblyopia, commonly referred to as lazy eye, that allows patients to watch TV within a virtual reality (VR) headset to ...

Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye in children that is based on watching TV shows.

In a dream come true for kids, rather than dissuading their pediatric patients from watching too much TV, physicians may now actually prescribe screen time as part of a therapeutic regimen. The FDA ...

A digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve vision correction over standard therapy in a phase 3 trial, according to its developer Luminopia.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, ...

'Luminopia One ', a treatment method mainly for children aged 4 to 7 years, that improves amblyopia by showing TV programs and movies using a VR headset and showing images with different contrast in ...

Amblyopia, better known as lazy eye, is the leading cause of vision loss in children and young adults; there’s about 1 million children, and about 4 million adults, who have this condition, and yet ...

Luminopia today announced the publication of positive Phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One TM —in Ophthalmology Ⓡ, the journal of the American Academy of ...